For the millions managing metabolic fatty liver disease, intermittent fasting and calorie restriction have emerged as go-to lifestyle tools — but a growing body of evidence suggests these interventions carry a significant hidden cost that practitioners rarely discuss with patients: accelerated muscle loss and a high likelihood of weight rebound that may leave the liver worse off than before treatment began.
This clinical review, published in Arquivos de Gastroenterologia, synthesizes recent randomized controlled trial data — including findings from Oh et al. — to quantify two underappreciated hazards in metabolic dysfunction-associated steatotic liver disease (MASLD) management. First, sarcopenia, already disproportionately prevalent in MASLD populations, is measurably worsened by time-restricted eating (TRE) and calorie restriction (CR) protocols. Muscle loss in this context is not merely cosmetic; it amplifies insulin resistance, elevates systemic inflammatory markers, and may accelerate hepatic fibrosis progression — the very outcomes these interventions aim to reverse. Second, weight cycling affects up to 60% of MASLD patients following dietary intervention, and each rebound episode drives hepatic fat re-accumulation alongside a distinct metabolic stress response that could compound fibrosis risk over time.
This analysis lands at a critical inflection point in liver disease research. MASLD has only recently replaced the older NAFLD nomenclature, and clinical guidelines are still catching up to the complexity of individualized management. The sarcopenia–MASLD axis is well-established in observational literature, but most TRE intervention trials have not been powered or designed to capture functional muscle outcomes — a significant methodological gap. The weight cycling concern mirrors decades of obesity research showing that yo-yo dieting carries independent cardiometabolic risk, yet this is rarely incorporated into liver disease trial design. This review is incremental rather than paradigm-shifting, but its value lies in forcing an explicit accounting of intervention trade-offs. Future trials that integrate resistance training protocols, protein intake monitoring, and long-term behavioral follow-up will be essential before TRE can be confidently recommended as a durable MASLD therapy.
